论文部分内容阅读
目的:观察中西医结合治疗晚期非小细胞肺癌患者的临床疗效及对血清肿瘤标志物的干预作用。方法:选择81例晚期非小细胞肺癌患者进行研究,按随机数字表法分为观察组41例与对照组40例。对照组采取化疗方案,观察组采取中西医结合治疗,比较2组治疗前后癌胚抗原(CEA)、神经特异性烯醇化酶(NSE)、细胞角蛋白21-1片段(CYFRA21-1)或糖类抗原125(CA125)等肿瘤标志物的水平及临床疗效。结果:观察组总有效率达95.1%,明显高于对照组的80.0%,差异有统计学意义(P<0.05)。治疗前,2组CEA、NSE、CYFRA21-1及CA125等肿瘤标志物比较,差异均无统计学意义(P>0.05)。治疗后,2组各标志物水平均较治疗前大幅降低,差异均有统计学意义(P<0.05);观察组各标志物水平均低于对照组,差异均有统计学意义(P<0.05)。结论:中西医结合治疗晚期非小细胞肺癌患者,可大幅降低血清肿瘤标志物水平,强化治疗效果,稳定患者病情。
Objective: To observe the clinical efficacy of traditional Chinese and western medicine in the treatment of advanced non-small cell lung cancer and its effect on serum tumor markers. Methods: A total of 81 patients with advanced non-small cell lung cancer were selected and divided into observation group (n = 41) and control group (n = 40) according to random number table. The control group was treated with chemotherapy. The observation group was treated with the combination of TCM and Western medicine. The CEA, NSE, CYFRA21-1 or the level of cytokeratin 21-1 Class antigen 125 (CA125) and other tumor markers and clinical efficacy. Results: The total effective rate in the observation group was 95.1%, which was significantly higher than that in the control group (80.0%), the difference was statistically significant (P <0.05). Before treatment, there were no significant differences between the two groups of CEA, NSE, CYFRA21-1 and CA125 tumor markers (P> 0.05). After treatment, the levels of each marker in two groups were significantly lower than those before treatment, the differences were statistically significant (P <0.05); the levels of each marker in the observation group were lower than those in the control group (P <0.05 ). Conclusion: Integrative treatment of advanced non-small cell lung cancer patients, can significantly reduce the level of serum tumor markers, and strengthen the treatment effect, stable patient’s condition.